Generation of rapid, strong and long-lasting antibody responses is crucial for development of effective vaccines against infectious diseases.
Vaccibody has over the last years generated promising pre-clinical data in different infectious disease models like SARS-CoV-2, Influenza, Ebola, Herpes Simplex Virus 2 and Tuberculosis.
The studies have shown that Vaccibody vaccines are able to protect against infectious diseases through generation of neutralizing antibodies and CD4+ T cell responses after a single administration with a needle-free jet injector.
Research is being conducted to leverage Vaccibody’s vaccine technology to develop vaccines to prevent or treat infectious diseases.